Terra Tech Corp (OTCMKTS:TRTC) 2 Prong Approach

Terra Tech Corp (OTCMKTS:TRTC) 2 Prong Approach

A hot OTC penny stock is Terra Tech Corp (TRTC) , which is a cannabis-focused agriculture company. Shares of the company are currently trading in the $0.33-$0.34 range, and the current market capitalization of the company is just over $118 million. Over a 52-week period, shares of the company have traded in the $0.08 to $0.75 range. The company engages in two primary fields of business – hydroponic produce (including produce, herbs, cigarettes and floral products) and cannabis products (including the design, marketing and sale of equipment). TRTC is looking to make a major move within the expanding cannabis industry. In fact, a number of other cannabis and medical marijuana companies are also seeing heavy trading volume right now in the OTC markets. Investors refer to this as the “Green Rush” – the great race to become a market leader within the emerging cannabis industry. Obviously, there is a tremendous amount of regulatory risk surrounding California-based TRTC (and every other company in the industry), but the growing consensus appears to be that this is a fast-growth field with enormous market potential. There’s one upcoming stock catalyst for TRTC, and that’s new ballot initiatives currently under consideration within California and Nevada that would further legalize marijuana use within the country. The company has already launched plans to operate medical marijuana facilities in Nevada through a number of subsidiaries. Recent concerns about a reverse stock split at the company seem to be over, and that could free up the stock to make a move upward if the ballot initiatives pass. What makes TRTC stand out from other competitors in the industry is its...

Penny Stocks to Buy Now: (NYSE:XCO), (NYSEMKT:AUMN)..

Penny Stocks to Buy Now: EXCO (NYSE:XCO), Golden Minerals (NYSEMKT:AUMN) and Banro (NYSEMKT:BAA)   In both the energy and mining sectors, sharp swings in commodity prices could turn several speculative penny stocks into real winners. It’s important to keep an eye not only on spot market prices for commodities such as oil, gas and gold, but also on long-term secular changes that are changing the balance between supply and demand.   Within the oil & gas sector, one major change has been the embrace of shale gas & oil exploration, and one company that could be poised to profit from this trend is EXCO Resources (NYSE:XCO), a Texas-based oil and natural gas company with strong shale resource plays within the continental United States. The company’s three big shale oil deposits are located in Texas, Louisiana and Appalachia.   Right now, investors are down on the company, with a consensus “sell” rating on the company. Shares of the company currently trade at $1.10, and the price target for the company is only $0.50. That would seem to suggest that shares of the company are going to collapse to a 52-week low ($0.51), compared to a 52-week high of $1.94.   But it’s exactly this pessimistic market sentiment that might lead to a real bargain for the stock. This is not a tiny company – the total market capitalization of EXCO is $290 million, with 65% institutional investor ownership. Think of this as a chance to go contrarian.   As recently as July 2015, RBC Capital Markets had upgraded the company from “Sector Underperform” to “Sector Perform.” There’s also been a...

Penny Stocks to Watch (NASDAQ:CTIC & NASDAQ:PTX)

Penny Stocks to Watch (NASDAQ:CTIC and NASDAQ:PTX)   Penny stocks to watch in this volatile market can be hard to find.  The bio-tech sector has some of the fastest-growing companies with the greatest potential for upside gain. Often, these companies can skyrocket to massive highs if a new clinical trial goes well, or if the company undergoes a major reorganization that brings in fresh investor capital. There are two biotech penny stocks – CTI BioPharma Corp (NASDAQ:CTIC) and Pernix Therapeutics (NASDAQ:PTX) that appear to have exactly that kind of upside potential.   The first on our list of penny stocks to watch, CTI BioPharma Corp (CTIC), offers targeted therapies for a wide range of blood-related cancers and other serious blood conditions. The stock is currently trading at $0.403, and over a 52-week period, has traded in a relatively narrow range of $0.25 to $1.75. However, right now, Piper Jaffray currently has a $0.75 price target for the stock, which has a market capitalization of over $120 million. There appear to be at least three primary catalysts for the stock to move nearly 50 percent higher. One is the recent release of data about PERSIST-2, a Phase 3 clinical trial from the company to develop a treatment for patients suffering from myelofibrosis, a debilitating blood condition that leads to lower quality of life and shortened survival time.   Another primary catalyst is the improved earnings picture for the company. On August 4, the company reported earnings per share of $0.07, topping analysts’ consensus estimates of $0.10. Finally, the third primary catalyst is the changing ownership structure of the company, with...